GALDY (Galderma Group AG) Research & Development: $245 Mil (TTM As of Dec. 2025)


GALDY Galderma Group AG GALDY
21 GF Score
Price $44.15
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Research & Development?

Galderma Group AG GALDY -0.17% 21 Research & Development is $245 Mil as of Dec. 2025. GuruFocus rates GALDY with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Galderma Group AG's Research & Development for the six months ended in Dec. 2025 was $141 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $245 Mil.

Galderma Group AG  (OTCPK:GALDY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Galderma Group AG Research & Development Related Terms

Galderma Group AG Research & Development Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Research & Development Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
342.60 315.90 287.00 260.00 245.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 150.00 135.00 125.00 104.00 141.00
GALDY
21GF Score
Galderma Group AG GALDY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $245 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $245 Mil mean?
Galderma Group AG (GALDY) has a Research & Development of $245 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Research & Development too high?
Galderma Group AG's current Research & Development is $245 Mil. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Research & Development compare to ZTS and UTHR?
Galderma Group AG's Research & Development of $245 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Research & Development is $245 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current Research & Development of $245 Mil. The current Research & Development is $245 Mil. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current Research & Development is $245 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score

Get the complete analysis for GALDY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.15
Price